Why Use the Oncotype DX Genomic Prostate Score Test?

The Oncotype DX GPS test gives you and your doctor more information for treatment conversations and decisions.

If you have been diagnosed with clinically low-, intermediate-, or high-risk prostate cancer, discussing management options with your doctor is typically the next step. The Oncotype DX GPS test gives you and your doctor more information for treatment conversations and decisions.

Oncotype DX GPS test is a genomic test, meaning that it measures the expression of certain genes in prostate cancer cells. The results are reported as a Genomic Prostate Score (GPS), which can help you and your doctor make decisions about a management plan that's best for you.1

Informing Your Treatment Decision

 

Your Oncotype DX Genomic Prostate Score May Help You Navigate Through Your Treatment Options

Your Oncotype DX Genomic Prostate Score will arm you with information that may help you take charge of your cancer treatment decision with confidence.

How the test can help you

The Oncotype DX GPS test measures the activity (also referred to as expression) of 17 select genes responsible for the growth and survival of tumor cells.

Tumor Analysis
Surveillance Surgery Radiation

  • Provides information that clarifies how the tumor may act and whether it is likely to be aggressive (adverse pathology).
  • Predicts whether you are likely to die from your cancer or have it spread to other parts of your body (metastasis) within 10 years of surgery.
In addition to your clinical factors, the Oncotype DX GPS test will provide information for you and your doctor to discuss next steps.

Why your tumor's gene activity matters

Not all prostate cancers are the same. However, many are lower risk and can be managed with regular doctor visits delaying or completely avoiding treatments like surgery or radiation.2

It’s important for you to understand your personal risk before deciding on a management plan—with this information in hand you can make a decision that is better suited to helping you live as long and healthy a life as possible. The Oncotype DX GPS test may help you and your health care team understand your individualized risk to inform decisions about what happens next—active surveillance or treatment.

Choosing active surveillance or treatment

If you have been diagnosed with very low-, low-, or favorable- intermediate-risk prostate cancer, you may be able to avoid aggressive treatment, while safely monitoring your prostate cancer through a program of regular check-ups and tests known as active surveillance.

Active surveillance is a treatment plan for patients whose tumor is not likely to be aggressive. It involves regular check-ups and ongoing testing, which may include1:

  • PSA (prostate-specific antigen) testing
  • Regular exams (DRE, digital rectal exams)
  • Repeat biopsy as recommended by your doctor
If you have been diagnosed with unfavorable- intermediate or high-risk prostate cancer, it is important to determine the appropriate method and level of treatment for you such as:

  • Surgery
  • Radiation
  • Hormonal therapy
The Oncotype DX GPS test provides both you and your doctor with meaningful insights and data to determine the optimal type and extent of treatment based on your personalized GPS test results.

When to have the test

If you have been recently diagnosed with clinically low-, intermediate-, and high-risk prostate cancer or have yet to decide on a management option, your biopsy tissue may be used to provide additional information about the aggressiveness of your tumor, which may help you choose the right treatment plan.

What’s needed to perform the test

The Oncotype DX GPS test uses a tissue sample from a biopsy performed within the last three years. So, if you’ve had a recent biopsy, no additional procedure is needed.

The test can predict the aggressiveness and biology of the prostate cancer without additional tests or having to remove the tumor by analyzing a very small sample of the tumor tissue.

REFERENCES

  1. Badani et al. Urol Pract. 2015.
  2. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.2.2020.
Making cancer care smarter.®
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.